Author:
Farrow Norma E.,Turner Megan C.,Salama April K. S.,Beasley Georgia M.
Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. American Cancer Society. Key Statistics in Melanoma Skin Cancer. https://www.cancer.org/cancer/melanoma-skin-cancer/about/key-statistics.html. 2018. https://www.cancer.org/cancer/melanoma-skin-cancer/about/key-statistics.html. Accessed 19 Nov 2018.
2. Mitsis DKL, Groman A, Beaupin LM, Salerno KE, Francescutti V, Skitzki JJ, et al. Trends in demographics, incidence, and survival in children, adolescents and young adults (AYA) with melanoma: a surveillance, epidemiology and end results (SEER) population-based analysis. J Clin Oncol. 2015;33:9058.
3. Max Fullah M, Viola F, Wiel BVD, Klop WMC, Józwiak K, Wouters MWJM, et al. External validation of the 8th edition melanoma staging system of the American Joint Committee on Cancer (AJCC): effect of adding EORTC sentinel node (SN) tumor burden criteria on prognostic accuracy in stage III. J Clin Oncol. 2018;36:9500.
4. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010;467(7315):596–9. https://doi.org/10.1038/nature09454.
5. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694–703. https://doi.org/10.1056/NEJMoa1210093.
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献